Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): A perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition

Brendan Frett, Robert V. Brown, Mingliang Ma, Wenhao Hu, Haiyong Han, Hong Yu Li

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

The global incidence of cancer is on the rise, and within the next decade, the disease is expected to become the leading cause of death worldwide. Forthcoming strategies used to treat cancers focus on the design and implementation of multidrug therapies to target complementary cancer specific pathways. A more direct means by which this multitargeted approach can be achieved is by identifying and targeting interpathway regulatory factors. Recent advances in understanding Nek2 (NIMA related kinase 2) biology suggest that the kinase potentially represents a multifaceted therapeutic target. In this regard, pharmacologic modulation of Nek2 with a single agent may effect several mechanisms important for tumor growth, survival, progression, and metastasis. We herein review the development of Nek2 as an oncology target and provide a succinct chronology of drug discovery campaigns focused on targeting Nek2.

Original languageEnglish (US)
Pages (from-to)5835-5844
Number of pages10
JournalJournal of Medicinal Chemistry
Volume57
Issue number14
DOIs
StatePublished - Jul 24 2014

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint Dive into the research topics of 'Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): A perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition'. Together they form a unique fingerprint.

  • Cite this